An evaluation of the strategy of maintenance of sinus rhythm by antiarrhythmic drug therapy after ablation and pacing therapy in patients with paroxysmal atrial fibrillation
View abstract on PubMed
Summary
This summary is machine-generated.Antiarrhythmic drug therapy after ablation and pacing significantly reduces the risk of developing permanent atrial fibrillation. However, this approach may increase heart failure episodes and hospitalizations, with no significant difference in long-term outcomes.
Area Of Science
- Cardiology
- Electrophysiology
- Internal Medicine
Background
- Permanent atrial fibrillation is a common complication following ablation and pacing therapy.
- Strategies to prevent or manage this progression are crucial for patient outcomes.
Purpose Of The Study
- To compare the efficacy of initial antiarrhythmic drug therapy versus no drug therapy in preventing permanent atrial fibrillation after atrioventricular junction ablation and pacing.
- To evaluate the impact of these strategies on quality of life, echocardiographic parameters, and adverse events.
Main Methods
- A multicentre randomized controlled trial involving 137 patients with severely symptomatic paroxysmal atrial fibrillation.
- Patients were assigned to either antiarrhythmic drug therapy (amiodarone, propafenone, flecainide, or sotalol) or no drug therapy post-ablation and pacing.
- Follow-up ranged from 12 to 24 months.
Main Results
- Antiarrhythmic drug therapy reduced the risk of developing permanent atrial fibrillation by 57% (21% vs 37%, P=0.02).
- Quality of life and echocardiographic parameters were similar between groups at 12 months.
- The drug arm experienced more heart failure episodes and hospitalizations (P=0.05).
Conclusions
- Conventional antiarrhythmic therapy is effective in reducing the incidence of permanent atrial fibrillation post-ablation and pacing.
- The development of permanent atrial fibrillation does not appear to be associated with adverse outcomes when heart rate is well-controlled by ablation and pacing.
- While reducing AF progression, antiarrhythmic drugs may increase risks of heart failure and hospitalization.